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Background
The fungus aspergillus causes a plethora of diseases in humans. Invasive pulmonary aspergillosis (IPA), a serious opportunistic infection seen in immunosuppressed or hospitalized patients with severe underlying diseases, is associated with high rates of morbidity and mortality. The diagnosis of IPA is a challenge in general hospital population. This study was undertaken to evaluate the utility of galactomannan (GM) assay in bronchoalveolar lavage (BAL) fluid and serum for the diagnosis of IPA in patients with nonresolving pneumonia in a tertiary care hospital.
Patients and methods
Patients with nonresolving pneumonia for whom both BAL and serum GM assays, along with BAL culture for fungus, were evaluated from January 2016 to June 2017. Results A total of 64 patients had the tests done in the study period. All the patients had more than one associated underlying risk factor. Diabetes was seen in 35 (64.68%) patients and steroid intake in 34 (53.12%). Aspergillus flavus was the most common fungus cultured. Moreover, 14 of the culture positives had a serum GM level of more than 0.5 GM index, and all culture positives had BAL GM level of more than 0.5 GM index. Receiver operating characteristic curves revealed a cutoff of 0.91 for serum GM, which provides sensitivity of 66% and specificity of 63% and 1.01 for BAL GM, with a sensitivity of 88% and specificity as of 78%. The all-cause mortality of 78.8% was noted with both BAL and BAL GM positive (P=0.001). Conclusion A combination of clinical, radiological, culture, and GM assay of both BAL and serum would help in the diagnosis of IPA in hospitalized patients with nonresolving pneumonia.
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bronchoalveolar lavage galactomannan assay, invasive pulmonary aspergillosis, serum galactomannan, Body Aspergillus is a fungus that causes a plethora of diseases in humans from allergic manifestation of allergic pulmonary aspergillosis to invasive pulmonary aspergillosis (IPA), the most severe type in the spectrum of pulmonary aspergillosis. IPA, a serious opportunistic infection seen in immunosuppressed or hospitalized patients with severe underlying diseases, is associated with high rates of morbidity and mortality [1] . Traditionally, IPA was always thought as a disease of neutropenic patients. Hence the criteria laid down by EORTC is used for the diagnosis of IPA in these subjects [2] . It is evident that even nonneutropenic patients are at risk of developing IPA. Invasive aspergillosis in nonneutropenic patients is associated with worse prognosis, with mortality rates exceeding 80%, probably owing to delay in diagnosis [3] [4] [5] . Not only is the clinical presentation nonspecific, the yield from diagnostic tests (compared with neutropenic patients) is lower [6, 7] .
In this setting, diagnosis of IPA is challenging in general hospital population with conditions like diabetes mellitus (DM), steroid use, and chronic obstructive pulmonary disease (COPD), among others. These emerging risk factors for IPA have not been well studied. The detection of circulating antigens in biologic fluids, such as serum or bronchoalveolar lavage (BAL) fluid, could aid in the diagnosis, where the gold standard − biopsy − is not feasible.
Galactomannan (GM) is found in the fungal wall of aspergillus and penicillium species. GM enzyme immunoassay performed on biological fluids like serum and BAL helps in the diagnosis of IPA. Not many studies have looked at the utility of GM assay in serum and BAL in patients with nonresolving pneumonia.
Hence, this study was undertaken to evaluate the utility of GM assay in BAL fluid and serum in patients with nonresolving pneumonia in a tertiary care hospital.
Patients and methods
This study was carried out at the Laboratory Services of the Department of Microbiology, SJMC, between January 2016 and June 2017. Ethical Approval of was obtained from the Institutional Ethics committee.
Inclusion
All patients for whom BAL assay was done as a part of the management protocol for nonresolving consolidation or persistent shadows in the chest radiograph, considered a sufficient radiological criterion [6] , after an adequate course of suitable antibiotics (of at least 7 days) with symptoms of cough, fever, and dyspnea after an informed consent were included. They were all started on antifungals based on clinical suspicion.
Spectrum bias (i.e. excluding important patient subgroups) was minimized by including BAL fluid specimens from all patients for whom the test was intended to be used (included all symptomatic patients fulfilling the host criteria as defined per EORTC/ MSG consensus definitions or without the classical EORTC host criteria presenting with unexplained lesions on chest radiography or chest computed tomography scan). Biopsy done was noted.
Exclusion BAL fluid was examined as part of the follow-up procedure and patients without recent radiological examination were excluded from the analysis. BAL samples from patients already on antifungals were excluded. Patients who had an alternate diagnosis (like tuberculosis and nocardia) established by BAL were excluded. Patients with suspected or known chronic pulmonary aspergillosis like aspergilloma were also excluded.
Sample collection Bronchoalveolar lavage sample
The samples collected following the standard protocols were centrifuged for 10 min at 10 000 rpm. The supernatant was used for GM assay, and the sediment was used for fungal culture.
Serum sample
Blood samples collected was used for the GM assay.
Fungal culture and identification
The sediment of the centrifuged BAL samples received for fungal or bacterial culture or for GM assay was used.
The processed BAL samples were subjected to standard microscopic examination and culture.
GM assay: the serum and BAL samples were subjected to GM assay using the commercially available kit (Platelia Aspertgillus Ag, Bio Rad, USA). It is a double-sandwich enzyme-linked immunosorbent assay. The test was carried out as per the manufacturer's instructions.
Cut off control: the optical density (OD) of each cut off control serum must be more than or equal to 0.300 and less than or equal to 0.800. Positive control: the index of the positive control serum must be greater than 1.50 more than 1.50, mean cut-off control OD. Negative control: the index of the negative control serum must be less than 0.40. I=OD negative control less than 0.40, mean cut-off control OD.
Flowchart

Statistical analysis
The McNemar c 2 test was used to compare sensitivity and specificity between the BAL DM and serum GM assays. The univariate analysis of contingency data was performed using a χ 2 test or Fisher's exact test. Although an GM index ratio 0.5 in BAL and serum GM was considered a priori as a reference for the diagnosis of IPA, receiver operating characteristic curve analysis was used to establish the best BAL and serum GM cutoff in our population (Flowchart 1).
Results
During this study period, 64 patients from whom a serum and BAL sample were received simultaneously for microbiological investigations were analyzed. No patient underwent biopsy of lung to prove IPA.
Distribution of age and sex
A total of 64 patients were enrolled in this study, of whom 48 (75%) were male and 16 (25%) were female patients. The age of the patients ranged between 18 and 90 years, and the mean age was 50.25 years.
Underlying risk factors
All the 64 patients had more than one associated underlying risk factor. Among the risk factors, diabetes was seen in 35 (64.68%) patients, steroid intake of any duration more than 15 days in the past 6 months in 34 (53.12%), renal failure in 29%, and acute respiratory distress syndrome in 20%, which were the risk factors seen in our patients (Tables 1 and 2) .
Radiological features
Of the 64 patients, 59 (92.18%) had consolidation with or without other features like cavity and pleural effusion. The other nine patients had fibrocavitatory disease. Nodules or classic feature of IPA like halo sign was not noted. Among the 15 culture positive patients, all of them had a positive BAL GM (BAL GM assay](mean GM, 3.77), and the serum assay (mean SGM, 2.11) was positive in 14 of them (Table 3) .
Overall, 14 of the culture positives had a serum GM level of more than 0.5 GM index, and 22 of the 49 (44.8%) culture negative had GM level of less than 0.5 ( Table 4 ).
All the 15 culture-positive patients had a BAL GM level of more than 1 GM index, of whom 12 had BAL GM values of more than 1.5 GM index.
Receiver operating characteristic curve
The figure shows the receiver operating characteristic curve of serum GM and BAL GM against BAL culture was considered as gold standard to predict IPA. The area under the curve) of BAL GM is 0.89 as compared with that of serum, which is 0.68.
Using the kit cutoff of 0.5, the sensitivity and specificity for BAL was found to be 100% with 95% confidence interval (CI) (81.5-100%) and 39% with 95% CI (25-55%), whereas for serum, the sensitivity is 85% with 95% CI (65-99%) and specificity is 46% with 95% CI (36-61%).
Although sensitivity for both the markers is found to be high, specificity is extremely low. This indicates that there may exist alternative cutoffs with a better trade of Tuberculosis(past history) 11 (17.18) between sensitivity and specificity. So optimizing sensitivity and specificity for different alternative cut-offs, we identified 0.91 for serum GM, which provides sensitivity of 66% and specificity of 63%, and 1.01 for BAL GM, with a sensitivity of 88% and specificity of 78% ( Figure 1 and Table 5 ).
A total of 45 patients died during the hospital stay, where 30 (66.6%) of them had mean serum GM positive results. Among the culture positives, the mean GM levels were significantly higher (2.5 vs. 1.2). In those who survived [8] , the GM levels were significantly lower.
The comparison of outcome with serum and BAL GM showed that there was a mortality of 78.8% with both BAL and BAL GM positive, and it was significant, with a P value of 0.001. There was no such significant association observed when either of them was positive or when both were negative. Serum-BAL − 0 1 0 BAL, bronchoalveolar lavage; GM, galactomannan. Table 3 Serum galactomannan levels in culture positive (C+) and culture negative(C−)
GM, galactomannan. Table 4 Bronchoalveolar lavage galactomannan levels in culture positive (C+) and culture negative(C−)
BAL, bronchoalveolar lavage; GM, galactomannan.
Figure 1
ROC curve for BAL GM and serum GM. BAL, bronchoalveolar lavage; GM, galactomannan; ROC, receiver operating characteristic.
Discussion
Invasive fungal infections especially IPA has been on the rise. The use of both serum GM assay and BAL GM assay in the diagnosis of IPA among patients satisfying the EORTC criteria has been well established [9] [10] [11] . However, the role of GM assay in the diagnosis of IPA in a general patient population without the well-described risk factors, usually managed in tertiary health care setup, has not been evaluated. Hence, in our study, we evaluated the serum and BAL GM levels in patients with nonresolving pneumonia.
All the patients had more than one associated underlying comorbid condition.
Uncontrolled DM was the most common host factor (not a classical host factor by EORTC criteria), associated in 54.68% of our patients. This was much higher than the other studies that have shown that ∼28
[12] to 34% [13] of their patients had diabetes. In diabetic patients, the ability of BAL macrophages to inhibit spore generation is reduced. This may result in rapid multiplication of the fungus in the airway [14] . However, the exact mechanism has not been well studied. Uncontrolled diabetes is a proven risk factor for mucormycosis, but it is not clear whether similar pathogenic mechanism exists for IPA as well.
Traditionally, high-dose, prolonged duration of steroids is a considered risk factor for IPA. However, there are no studies correlating the exact glucocorticoid dose and duration of treatment with the risk for invasive aspergillosis. There is evidence in literature to state that even one week of steroids can be a risk factor for IPA, including inhaled steroids [15, 16] Studies have shown that glucocorticoids affect virtually every cell type involved in immune and inflammatory response, with greater than 50% reduction in circulating lymphocytes within 4 h of injection of 400 mg of hydrocortisone, and its effect lasts for 24 h [17] . Hence, any use of steroids in the 3 months before admission was recorded as a risk factor. History of steroid use was elicited in 34 (53.1%) patients. This was lower than an Italian study in nonneutropenic patients, where 83% of their patients used steroids in some form. This could be because they had a higher proportion of patients with COPD (69%). In our study, we had only 15.6% of patients with COPD [18] .
The other host factors like renal failure (in 45%) and cardiac failure (20%) have not been described in previous studies as a risk factor. ICU stay is the next well-studied population after neutropenics as a risk factor for IPA [6] . Overall, 20% of our patients had acute respiratory distress syndrome and were in ICU. Unlike other series, we had very few patients with liver failure (6%) [6] .
The complex interaction between the environment (construction, fungal spores in the air, etc.) and host results in multifarious manifestations of aspergillosis, which are yet to be studied in detail. Hence, further large-scale multicentric studies are needed to address this.
Among our patients, consolidation was the most common finding, which was observed in 59 (92.18%) of the 64 patients. No patient had a halo sign. The most typical imaging findings including the halo sign and the air crescent sign have shown high sensitivity (80%) and specificity (60-98%) in neutropenic patients. None of our patients had these signs. Other studies also have found that both signs are uncommon and have a lower sensitivity (5-24%) for IPA. To add to the ambiguity, these radiological patterns can be found even in noninfectious processes in nonneutropenic patients [19] . Hence, it is safe to assume that radiological patterns are not specific in nonneutropenic patients, and this cannot form the only basis of suspicion of IPA.
BAL samples from all the 64 patients subjected to microscopy and fungal culture yielded positive culture [20] . Probably there is a change in the epidemiology in our country and more studies are required to establish A. flavus as pathogen in IPA [8] . Culture was used as a gold standard as there is evidence that isolation of Aspergillus spp. from BAL in nonneutropenic patients especially COPD might have equal importance as in immunocompromised patients, and can indicate a diagnostic possibility of IPA. Aspergillus spp. isolation from BAL samples in the right clinical scenario might indicate IPA [21] .
Hence, we analyzed the performance of both serum and BAL GM individually as well as together, and compared it with BAL culture, as culture is still considered the conventional gold standard. GM index at kit cutoff of more than or equal to 0.5 was considered as positive for both serum as well the BAL samples as recommended by the manufacturer.
The serum GM was positive among 41 (64%) patients . This is much higher than the study on a similar population by Cai et al. [22] (40%) using the same cut-off of 0.5 GM index. The mean value of GM was 2.11 GM index in the culture positives, which was significantly higher than 1.45 GM index in culture negative group. This was similar to the values obtained in probable IPA as per EORTC criteria in previous studies as well [7, 8] . Hence, serum GM can be used to suspect IPA in even nonneutropenic patients in the right clinical setting.
At a serum GM cutoff of 0.5, the sensitivity was 85% with 95% CI (65-99%) and specificity is 46% with 95% CI (36-61%). At a cutoff of 0.91 for serum GM, sensitivity was 66% and specificity was 63%. This was much lower than in neutropenic patients at a cutoff of 1 (sensitivity 100% and specificity of 85%) [23] .
BAL GM has been well studied in neutropenic patients with IPA. It is not clear from the literature if this could be extrapolated to nonneutropenic patients as well [7] .
The BAL GM was raised more than the kit cut-off of 0.5 among 46 patients. In the culture positive and negative groups, the mean value of GM was 3.77 and 1.137, respectively, and was statistically significant (P=0.0001). Zhuang et al. [24] found 30% of culture positives were BAL GM positive in nonneutropenic patients. In our population, all culture positives were GM positive.In nonneutropenic patients, optimal cutoffs have been studied and found to be in the range of 0.5-1.25 GM index. In a meta-analysis, the cutoff was arrived at 1 GM index (mixed population of neutropenic and nonneutropenic) [11] .
In unselected patients in a tertiary care hospital like ours, the GM assay in BAL at GM index of 0.5 showed the sensitivity and specificity of 100%, with 95% CI (81.5-100%), and 39%, with 95% CI (25-55%), respectively. This is similar to other studies in a similar unselected nonneutropenic patients [8, 24, 25] .
In our study, at a cutoff of 1.01 for BAL GM provides sensitivity of 88% and specificity of 78%. This is higher than the other two studies by Haese No study has looked at the utility of both BAL and serum GM like ours in general hospital patients with nonresolving pneumonia.
On analysis of the mortality data, the significantly higher all-cause mortality in patients who had high BAL and serum GM levels is similar to a study by Cai et al. [22] . Airway invasive aspergillus is more common than angioinvasive in nonneutropenic patients [1] , but our patients had high serum GM positivity in spite of being nonneutropenic. It is not clear from the literature when in the course of IPA the serum GM becomes positive. Hence, our patients probably had a delayed diagnosis of IPA when it crossed the threshold of airway invasiveness to become angioinvasive. This is reflected in all-cause mortality.
Our study has some limitations. First, the performance and timing of bronchoscopy was determined by the physician. Hence, samples could have been collected at different time periods of the fungal disease process. Second, the BAL protocols, are not standardized; variable amount of saline instilled and collected fluid may affect GM concentrations. The sample size was small; hence, a larger study will make these results applicable.
The strength of this study was that paired serum sample was obtained for all patients. As the spectrum bias was minimized, we might be estimating the performance of a BAL and serum GM in a population that represents the intended-use population, and a higher cutoff for GM levels was obtained.
Conclusion
Early diagnosis of IPA that is non-culture based with a short turnaround time for a better patient outcome is the need of the hour. Till such time that the utility of fungal molecular diagnostics is critically evaluated and introduced into routine diagnostics, GM assay using serum and BAL will contribute substantially to the diagnosis of IPA.
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